News | 11 January 2026
Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The supplements are made using only vegetarian-sourced ingredients
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
The approval introduces a needle-free alternative to injectable GLP-1 therapies
India’s pharmaceutical sector stands at a pivotal inflection point
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company previously completed a $150 million venture investment, acquisition, and recapitalization
Subscribe To Our Newsletter & Stay Updated
